{
  "asset": "DARZALEX (daratumumab)",
  "query_terms": [
    "DARZALEX (daratumumab)",
    "daratumumab",
    "DARZALEX"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT03500445",
      "title": "Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Myeloma",
        "Multiple Myeloma"
      ],
      "lead_sponsor": "University of Chicago",
      "collaborators": [
        "Janssen Scientific Affairs, LLC",
        "Amgen"
      ],
      "interventions": [
        "Daratumumab",
        "Carfilzomib",
        "Lenalidomide",
        "Dexamethasone"
      ],
      "last_update": "2025-10-03",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03500445"
    },
    {
      "nct_id": "NCT03289299",
      "title": "Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Smoldering Multiple Myeloma"
      ],
      "lead_sponsor": "International Myeloma Foundation",
      "collaborators": [
        "Amgen",
        "Janssen Scientific Affairs, LLC",
        "Celgene",
        "Trevie, Inc."
      ],
      "interventions": [
        "Carfilzomib",
        "Lenalidomide",
        "Daratumumab",
        "Dexamethasone"
      ],
      "last_update": "2023-12-12",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03289299"
    },
    {
      "nct_id": "NCT04396496",
      "title": "A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "POEMS Syndrome"
      ],
      "lead_sponsor": "University of Arkansas",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "Daratumumab Injection"
      ],
      "last_update": "2023-11-13",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04396496"
    },
    {
      "nct_id": "NCT03384654",
      "title": "An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Vincristine",
        "Prednisone",
        "Doxorubicin",
        "Peg-asparaginase",
        "Cyclophosphamide",
        "Cytarabine",
        "6-mercaptopurine",
        "Methotrexate"
      ],
      "last_update": "2025-05-25",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03384654"
    },
    {
      "nct_id": "NCT07075510",
      "title": "A Phase I/II Study of Subcutaneous Daratumumab Administration in the Anterior Upper Thigh Vs Abdomen in Patients With Plasma Cell Disorders",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Plasma Cell Disorder"
      ],
      "lead_sponsor": "University of Maryland, Baltimore",
      "collaborators": [
        "Johnson & Johnson"
      ],
      "interventions": [
        "Daratumumab Injection"
      ],
      "last_update": "2025-10-29",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07075510"
    },
    {
      "nct_id": "NCT04140162",
      "title": "Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "University of Michigan Rogel Cancer Center",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "Daratumumab",
        "Lenalidomide",
        "Bortezomib",
        "Dexamethasone"
      ],
      "last_update": "2024-10-09",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04140162"
    },
    {
      "nct_id": "NCT05849610",
      "title": "An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "High-Risk de Novo Multiple Myeloma"
      ],
      "lead_sponsor": "PETHEMA Foundation",
      "collaborators": [
        "Janssen Pharmaceutica N.V., Belgium"
      ],
      "interventions": [
        "Daratumumab",
        "Bortezomib",
        "Lenalidomide",
        "Teclistamab",
        "Talquetamab"
      ],
      "last_update": "2025-03-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05849610"
    },
    {
      "nct_id": "NCT03187262",
      "title": "A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory WaldenstrÃ¶m Macroglobulinemia",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "WaldenstrÃ¶m Macroglobulinemia"
      ],
      "lead_sponsor": "Dana-Farber Cancer Institute",
      "collaborators": [
        "Janssen, LP"
      ],
      "interventions": [
        "Daratumumab"
      ],
      "last_update": "2022-11-23",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03187262"
    },
    {
      "nct_id": "NCT03447808",
      "title": "Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "lead_sponsor": "Jennifer Woyach",
      "collaborators": [],
      "interventions": [
        "Daratumumab",
        "Ibrutinib",
        "Laboratory Biomarker Analysis",
        "Pharmacological Study"
      ],
      "last_update": "2026-01-07",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03447808"
    },
    {
      "nct_id": "NCT04910568",
      "title": "An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Multiple Myeloma"
      ],
      "lead_sponsor": "Genentech, Inc.",
      "collaborators": [
        "Hoffmann-La Roche"
      ],
      "interventions": [
        "Cevostamab",
        "Tocilizumab",
        "Pomalidomide",
        "Daratumumab",
        "Dexamethasone"
      ],
      "last_update": "2025-12-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04910568"
    }
  ]
}